Frankfurt - Delayed Quote EUR

Rocket Pharmaceuticals, Inc. (9IP1.F)

9.94

+0.32

+(3.37%)

截至 8:16:34 AM GMT+1。開市。

Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 15 days ago

RCKTW
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

CRANBURY, N.J., January 02, 2025--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, in San Francisco, California. Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present on Monday, January 13, at 3:45 p.m. PT and host investor meetings throu

Business Wire 28 days ago

RCKT

RCKTW
Wedbush starts Rocket Pharmaceuticals with Outperform into ‘inflection year’

Wedbush initiated coverage of Rocket Pharmaceuticals (RCKT) with an Outperform rating and $32 price target The analyst believes 2025 “should be an inflection year” for Rocket with multiple clinical and regulatory catalysts “potentially creating strong momentum” with the shares trading near 52-week lows. Rocket’s RP-A501 for Danon disease has potential to be a $1B commercial opportunity, the analyst tells investors in a research note. The firm thinks an accelerated approval pathway may be possibl

TipRanks 30 days ago

RCKT

RCKTW
Rocket Pharmaceuticals' Continued Pipeline Development to Support Long-Term Growth Potential, Wedbush Says

Rocket Pharmaceuticals' (RCKT) continued pipeline development together with its in-house manufacturi

Premium
MT Newswires last month

RCKTW
Rocket Pharmaceuticals, Inc. (RCKT): Is This Gene Therapy Stock a Good Buy Right Now?

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stands against the other gene therapy stocks. Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or […]

Insider Monkey last month

RCKTW
Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'

Jefferies initiated a "buy" rating on Rocket Pharmaceuticals, based on the biotech firm's experimental gene therapies.

Investopedia last month

RCKTW
Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

CRANBURY, N.J., December 11, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced today the pricing of an upsized underwritten public offering of 13,200,000 shares of its common stock at a public offering price of $12.50 per share. The gross proceeds to Rocket from the offering, before deducting underwriting discounts and commissions and offe

Business Wire last month

RCKT

RCKTW
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

CRANBURY, N.J., December 10, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced today that it intends to offer and sell $150 million of shares of its common stock in an underwritten public offering. In addition, Rocket intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of shares of its common stock

Business Wire last month

RCKT

RCKTW
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference

CRANBURY, N.J., November 26, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 7th Annual Evercore HealthCONx Conference in Miami, Florida. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat on Tuesday, December 3, at 1:45 p.m. ET and host investor meetings throughou

Business Wire 2 months ago

RCKT

RCKTW
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst

On Monday, Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) presented long-term safety and efficacy results from the Phase 1 study of RP-A501 in male patients with Danon disease. Danon disease is a rare X-linked dominant genetic disorder that manifests with the clinical triad of cardiomyopathy (stiff heart muscles), skeletal myopathy (weakness), and intellectual disability. Also Read: FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides Danon dise

Benzinga 2 months ago

RCKTW
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference

CRANBURY, N.J., November 18, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, presented long-term safety and efficacy results from the Phase 1 RP-A501 study which showed that RP-A501 was generally well tolerated and all evaluable Danon disease patients demonstrated LAMP2 protein expression at 12 months (sustained up to 60 months) and reduction of l

Business Wire 2 months ago

RCKT

RCKTW
Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions

CRANBURY, N.J., November 12, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the company will be presenting new data on the results of the RP-A501 Phase 1 trial to treat patients with Danon disease at the American Heart Association’s 2024 Late-Breaking Science sessions being held from November 16-18, 2024 in Chicago, Illinois.

Business Wire 2 months ago

RCKT

RCKTW
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus

RCKT incurs narrower-than-expected third-quarter 2024 loss. The company provides updates on its pipeline candidates.

Zacks 2 months ago

RCKTW
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference

CRANBURY, N.J., November 08, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the UBS Global Healthcare Conference in Rancho Palos Verdes, CA. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat on Tuesday, November 12, at 5:00 p.m. PT.

Business Wire 2 months ago

RCKT

RCKTW
Rocket Pharmaceuticals: Q3 Earnings Snapshot

CRANBURY, N.J. (AP) — Rocket Pharmaceuticals Inc. RCKT) on Thursday reported a loss of $66.7 million in its third quarter. On a per-share basis, the Cranbury, New Jersey-based company said it had a loss of 71 cents.

Associated Press Finance 2 months ago

RCKTW
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

CRANBURY, N.J., November 07, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the third quarter ending September 30, 2024.

Business Wire 2 months ago

RCKT

RCKTW
Here's Why We're Watching Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Simply Wall St. 2 months ago

RCKT

RCKTW
Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

CRANBURY, N.J., September 17, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that all patients have been enrolled in the global, pivotal Phase 2 clinical trial evaluating RP-A501 to treat male patients with Danon disease.

Business Wire 4 months ago

RCKT

RCKTW
Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors

CRANBURY, N.J., September 10, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of Mikael Dolsten, M.D., Ph.D., as an independent director to its Board of Directors. Dr. Dolsten is an accomplished industry executive with extensive global pharmaceutical management experience.

Business Wire 4 months ago

RCKT

RCKTW
Rocket Stock Down More Than 30% in Past Six Months: Here's Why

The recent regulatory setbacks related to RCKT's pipeline candidate, Kresladi (marnetegragene autotemcel) weigh heavily on the stock.

Zacks 4 months ago

RCKTW

表現總覽

回報	9IP1.F	S&P 500
年初至今	-8.25%	+2.78%
1 年	-62.98%	+23.27%
3 年	-24.15%	+36.99%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Rocket Pharmaceuticals, Inc. (9IP1.F)

Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Wedbush starts Rocket Pharmaceuticals with Outperform into ‘inflection year’

Rocket Pharmaceuticals' Continued Pipeline Development to Support Long-Term Growth Potential, Wedbush Says

Rocket Pharmaceuticals, Inc. (RCKT): Is This Gene Therapy Stock a Good Buy Right Now?

Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'

Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference

Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference

Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions

Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus

Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference

Rocket Pharmaceuticals: Q3 Earnings Snapshot

Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

Here's Why We're Watching Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Situation

Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors

Rocket Stock Down More Than 30% in Past Six Months: Here's Why

表現總覽